V
Vishal Kukreti
Researcher at Princess Margaret Cancer Centre
Publications - 178
Citations - 3003
Vishal Kukreti is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 26, co-authored 166 publications receiving 2655 citations. Previous affiliations of Vishal Kukreti include University of Toronto & University Health Network.
Papers
More filters
Journal ArticleDOI
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
Craig B. Reeder,Donna E. Reece,Vishal Kukreti,Christine Chen,Suzanne Trudel,Joseph G. Hentz,Brie N. Noble,Nicholas A. Pirooz,Jacy Spong,Jesus Giovanni Piza,V H J Zepeda,Joseph R. Mikhael,Jose F. Leis,P L Bergsagel,R Fonseca,Alexander Keith Stewart +15 more
TL;DR: In conclusion, CyBorD produces a rapid and profound response in patients with newly diagnosed multiple myeloma with manageable toxicity.
Journal ArticleDOI
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
Craig B. Reeder,Donna E. Reece,Vishal Kukreti,Christine Chen,Suzanne Trudel,Kristina Laumann,Joseph G. Hentz,Nicholas A. Pirooz,Jesus Giovanni Piza,Rodger E. Tiedemann,Joseph R. Mikhael,Peter Leif Bergsagel,Jose F. Leis,Rafael Fonseca,Alexander Keith Stewart +14 more
TL;DR: A 3-drug combination of bortezomib, cyclophosphamide, and dexamethasone (CyBorD) in newly diagnosed symptomatic patients in relapsed multiple myeloma patients was examined.
Journal ArticleDOI
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.
Lisa K. Hicks,Harriet Bering,Kenneth R. Carson,Judith Kleinerman,Vishal Kukreti,Alice Ma,Brigitta U. Mueller,Sarah H. O'Brien,Marcelo C. Pasquini,Ravindra Sarode,Lawrence A. Solberg,Adam E. Haynes,Mark Crowther +12 more
TL;DR: Five tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit are identified by the American Board of Internal Medicine Foundation.
Journal ArticleDOI
Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
Christine I. Chen,P. Leif Bergsagel,Harminder Paul,Wei Xu,Anthea Lau,Nimisha Dave,Vishal Kukreti,Ellen Wei,Chungyee Leung-Hagesteijn,Zhihua Li,Joseph Brandwein,Mariela Pantoja,James B. Johnston,Spencer B. Gibson,Tiffany A. Hernandez,David Spaner,Suzanne Trudel +16 more
TL;DR: A lenalidomide-induced molecular signature provides insights into its immunomodulatory mechanisms of action in CLL and is clinically active as first-line CLL therapy and is well-tolerated if a conservative approach with slow dose escalation is used.
Journal ArticleDOI
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
Sarit Assouline,Torsten Holm Nielsen,Stephen Yu,Miguel Alcaide,Lauren Chong,David MacDonald,Axel Tosikyan,Vishal Kukreti,Abbas Kezouh,Tina Petrogiannis-Haliotis,Marco A. Albuquerque,Daniel Fornika,Sepideh Alamouti,Remi Froment,Celia M. T. Greenwood,Kathleen Klein Oros,Errol Camglioglu,Ayushi Sharma,Rosa Christodoulopoulos,Caroline Rousseau,Nathalie A. Johnson,Michael Crump,Ryan D. Morin,Ryan D. Morin,Koren K. Mann +24 more
TL;DR: It is concluded that panobinostat induces very durable responses in some patients with relapsed DLBCL, and early responses can be predicted by mutations in MEF2B or a significant change in ctDNA level at 15 days after treatment initiation.